Acute pseudobulbar palsy as the initial presentation of intravascular lymphomatosis.

We describe the case of a 76-year-old male patient who developed acute manifestations of pseudobulbar palsy without a history of stroke or vascular risk factors as the first manifestation of intravascular lymphomatosis. Neurological symptoms of acute pseudobulbar palsy appeared on the second postoperative day after transurethral prostatectomy for the treatment of prostatic hypertrophy. Intravascular lymphomatosis was diagnosed from microscopic findings and immunohistochemical staining of the surgical specimen.

Genetic characterization of the paraimmunoblastic variant of small lymphocytic lymphoma/chronic lymphocytic leukemia: A case report and review of the literature.

Paraimmunoblastic variant of small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) is characterized by a diffuse proliferation of cells, called paraimmunoblasts, normally located on the pseudoproliferation centers. Patients usually present with multiple lymphadenopathies and a rapid and aggressive progression of the disease. We report a case with paraimmunoblastic variant of SLL/CLL genetically well-characterized by conventional cytogenetics, comparative genomic hybridization (CGH), IgH/BCL-1, IgH/BCL-2, and p53 fluorescent in situ hybridization (FISH) probes and polymerase chain reaction (PCR) for detection of IgH/BCL-2 translocation.

Contribution of cytogenetics and in situ hybridization to the study of monoclonal gammopathies of undetermined significance.

Monoclonal gammopathies of undetermined significance (MGUS) are characterized by the presence of a monoclonal protein in serum in quite asymptomatic patients. Ten to 33% of MGUS patients eventually will develop overt multiple myeloma, but no single laboratory test exists that can predict changes toward a malignant evolution. The aim of the present study was to apply conventional cytogenetics, the MAC (morphology, antibody, chromosome) method and fluorescence in situ hybridization (FISH) techniques in a series of 50 MGUS patients and 4 "smoldering" multiple myeloma patients to test the usefulness of their approaches as predictive methodologies.